Hemodynamic parameters and systemic leukocyte counts
| . | Treatment . | ||||
|---|---|---|---|---|---|
| PBS . | Ang-II . | Ang-II and anti-TNFα . | Ang-II and anti-IL-4 . | Ang-II and anti-TNFαand anti-IL-4 . | |
| MABP, mm Hg | 111.8 ± 2.7 | 110.2 ± 4.6 | 107.6 ± 6.2 | 112.6 ± 2.0 | 113.9 ± 2.9 |
| Arteriolar diameter | 22.4 ± 1.7 | 21.0 ± 1.6 | 21.0 ± 1.3 | 22.2 ± 1.9 | 23.4 ± 2.7 |
| Arteriolar shear rate, s−1 | 1367.4 ± 122.8 | 1234.6 ± 98.6 | 1147.8 ± 97.1 | 1158.0 ± 95.7 | 1161.7 ± 80.5 |
| Venular diameter | 28.6 ± 1.2 | 29.6 ± 1.3 | 30.7 ± 2.1 | 29.3 ± 1.6 | 31.0 ± 4.0 |
| Venular shear rate, s−1 | 527.4 ± 83.9 | 468.6 ± 71.0 | 541.6 ± 57.8 | 503.3 ± 46.8 | 562.6 ± 64.9 |
| Systemic leukocyte counts, cells/μL | 11 860.2 ± 809.2 | 10 092.3 ± 685.6 | 10 427.3 ± 494.1 | 9995.2 ± 836.7 | 11 104.0 ± 525.8 |
| . | Treatment . | ||||
|---|---|---|---|---|---|
| PBS . | Ang-II . | Ang-II and anti-TNFα . | Ang-II and anti-IL-4 . | Ang-II and anti-TNFαand anti-IL-4 . | |
| MABP, mm Hg | 111.8 ± 2.7 | 110.2 ± 4.6 | 107.6 ± 6.2 | 112.6 ± 2.0 | 113.9 ± 2.9 |
| Arteriolar diameter | 22.4 ± 1.7 | 21.0 ± 1.6 | 21.0 ± 1.3 | 22.2 ± 1.9 | 23.4 ± 2.7 |
| Arteriolar shear rate, s−1 | 1367.4 ± 122.8 | 1234.6 ± 98.6 | 1147.8 ± 97.1 | 1158.0 ± 95.7 | 1161.7 ± 80.5 |
| Venular diameter | 28.6 ± 1.2 | 29.6 ± 1.3 | 30.7 ± 2.1 | 29.3 ± 1.6 | 31.0 ± 4.0 |
| Venular shear rate, s−1 | 527.4 ± 83.9 | 468.6 ± 71.0 | 541.6 ± 57.8 | 503.3 ± 46.8 | 562.6 ± 64.9 |
| Systemic leukocyte counts, cells/μL | 11 860.2 ± 809.2 | 10 092.3 ± 685.6 | 10 427.3 ± 494.1 | 9995.2 ± 836.7 | 11 104.0 ± 525.8 |
Parameters (mean ± SEM in animals used for intravital microscopy studies) were measured 4 hours after the intraperitoneal injection of PBS (n = 5) or Ang-II (1 nM) in animals untreated (n = 5) or pretreated with anti-TNFα, anti-IL-4 (n = 6), or a combination of both antisera (n = 4).